Evotec SE
EVO · XNASCIK 1412558fmd_10FQS8NVZEZ73SQ3KEY1NXKK5DManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Dec 31, 2025, 7 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|
| Total revenues | 446 | 501 | 618 | 751 | 781 | 797 |
| Cost of revenue | 314 | 375 | 466 | 577 | 606 | 682 |
| Gross profit | 133 | 126 | 152 | 174 | 175 | 115 |
| Research and development | 58 | 64 | 72 | 77 | 69 | 51 |
| Selling, general and administrative | 66 | 77 | 105 | 156 | 170 | 188 |
| Operating income | 63 | 49 | 41 | 21 | (48) | (143) |
| Interest expense | 7 | 8 | 9 | 13 | – | – |
| Income before taxes | 57 | 26 | 237 | (154) | (81) | (194) |
| Income tax expense | 19 | 20 | 21 | 22 | 3 | 2 |
| Net income from continuing operations | 37 | 6 | 216 | (176) | (84) | (196) |
| Net income | 38 | 6 | 216 | (176) | (84) | (196) |